PEPG Quote, Financials, Valuation and Earnings

Immuneering Corp. has a net margin of -- compared to PepGen Inc.'s net margin of --. PepGen Inc.'s return on equity of -80.35% beat Immuneering Corp.'s return on equity of -78.54%.

PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 81.16%. On the other hand Immuneering Corp. has an analysts' consensus of $16.83 which suggests that it could grow by 193.26%. Given that Immuneering Corp. has higher upside potential than PepGen Inc., analysts believe Immuneering Corp. is more attractive than PepGen Inc..

PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immuneering Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Immuneering Corp. pays out -- of its earnings as a dividend.

PepGen Inc. quarterly revenues are --, which are smaller than Immuneering Corp. quarterly revenues of --. PepGen Inc.'s net income of -$18M is lower than Immuneering Corp.'s net income of -$15M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Immuneering Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 323.21x for Immuneering Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to PepGen Inc.'s net margin of 33.68%. PepGen Inc.'s return on equity of -80.35% beat Merck & Co., Inc.'s return on equity of 39.63%.

PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 81.16%. On the other hand Merck & Co., Inc. has an analysts' consensus of $108.04 which suggests that it could grow by 9.94%. Given that PepGen Inc. has higher upside potential than Merck & Co., Inc., analysts believe PepGen Inc. is more attractive than Merck & Co., Inc..

PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.34% to investors and pays a quarterly dividend of $0.85 per share. PepGen Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

PepGen Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. PepGen Inc.'s net income of -$18M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 3.88x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of -255.85%. PepGen Inc.'s return on equity of -80.35% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 81.16%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -73.1%. Given that PepGen Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe PepGen Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. PepGen Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

PepGen Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. PepGen Inc.'s net income of -$18M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 6.14x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of -45.06%. PepGen Inc.'s return on equity of -80.35% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

PepGen Inc. has a consensus price target of $10.00, signalling upside risk potential of 81.16%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.43 which suggests that it could fall by -8.41%. Given that PepGen Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe PepGen Inc. is more attractive than Sarepta Therapeutics, Inc..

PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.

PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

PepGen Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. PepGen Inc.'s net income of -$18M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 0.95x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.